Real time insider trading transaction history:

  • Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
Time period
Insider Trading Transactions for Chevallard Daniel R.
Common stock purchase or sale:
Transaction
Date
Reported
DateTime
Company Symbol Insider
Relationship
Shares
Traded
Average
Price
Total
Amount
Shares
Owned
Filing
2022-08-25
Sale
2022-08-29
9:14 pm
Viracta Therapeutics Inc. VIRX Chevallard Daniel R.
CFO
COO
3,655 $4.0162 $14,679 158,153
(Direct)
View
2022-05-25
Sale
2022-05-27
5:27 pm
Viracta Therapeutics Inc. VIRX Chevallard Daniel R.
CFO
COO
3,596 $1.9011 $6,836 161,808
(Direct)
View
2022-02-25
Sale
2022-03-01
9:10 pm
Viracta Therapeutics Inc. VIRX Chevallard Daniel R.
CFO
COO
3,998 $2.7795 $11,112 165,404
(Direct)
View
2021-11-25
Sale
2021-11-29
7:48 pm
Viracta Therapeutics Inc. VIRX Chevallard Daniel R.
CFO
COO
7,579 $4.8112 $36,464 169,402
(Direct)
View
2019-07-01
Sale
2019-07-02
5:41 pm
Regulus Therapeutics Inc. RGLS Chevallard Daniel R.
CFO
2,669 $1.3115 $3,500 77,870
(Direct)
View
2019-05-14
Sale
2019-05-16
5:21 pm
Regulus Therapeutics Inc. RGLS Chevallard Daniel R.
CFO
10,000 $1.4089 $14,089 88,039
(Direct)
View
2019-04-01
Sale
2019-04-03
4:16 pm
Regulus Therapeutics Inc. RGLS Chevallard Daniel R.
CFO
3,253 $0.9814 $3,192 9,372
(Direct)
View

Stock options: Exercise, Award, Grant, Conversion
Transaction
Date
Reported
DateTime
Exercisable
Expiration
Company Symnbol Insider
Relationship
Shares
Traded
Conversion
Price
Shares
Owned
Filing
2022-08-25
Exercise
2022-08-29
9:14 pm
N/A
N/A
Viracta Therapeutics Inc. VIRX Chevallard Daniel R.
CFO
COO
6,889 $0 158,153
(Direct)
View
2022-05-25
Exercise
2022-05-27
5:27 pm
N/A
N/A
Viracta Therapeutics Inc. VIRX Chevallard Daniel R.
CFO
COO
6,889 $0 161,808
(Direct)
View
2022-03-17
Option Award
2022-03-18
5:35 pm
N/A
2032-03-17
Viracta Therapeutics Inc. VIRX Chevallard Daniel R.
CFO
COO
195,000 $0 195,000
(Direct)
View
2022-02-25
Exercise
2022-03-01
9:10 pm
N/A
N/A
Viracta Therapeutics Inc. VIRX Chevallard Daniel R.
CFO
COO
6,889 $0 165,404
(Direct)
View
2021-11-25
Exercise
2021-11-29
7:48 pm
N/A
N/A
Viracta Therapeutics Inc. VIRX Chevallard Daniel R.
CFO
COO
13,777 $0 169,402
(Direct)
View
2021-09-28
Exercise
2021-09-29
6:04 pm
N/A
N/A
Viracta Therapeutics Inc. VIRX Chevallard Daniel R.
CFO
COO
10,000 $0.9 155,577
(Direct)
View
2021-09-28
Exercise
2021-09-29
6:04 pm
N/A
2029-07-30
Viracta Therapeutics Inc. VIRX Chevallard Daniel R.
CFO
COO
10,000 $0 155,577
(Direct)
View
2021-05-28
Exercise
2021-06-01
5:49 pm
N/A
N/A
Viracta Therapeutics Inc. VIRX Chevallard Daniel R.
CFO
COO
12,000 $0.9 155,577
(Direct)
View
2021-05-28
Exercise
2021-06-01
5:49 pm
N/A
2029-07-30
Viracta Therapeutics Inc. VIRX Chevallard Daniel R.
CFO
COO
12,000 $0 155,577
(Direct)
View
2021-03-26
Option Award
2021-03-30
8:00 pm
N/A
2031-03-26
Viracta Therapeutics Inc. VIRX Chevallard Daniel R.
CFO
COO
78,912 $0 78,912
(Direct)
View
2021-02-24
Ownership
2021-02-24
8:10 pm
N/A
N/A
SUNESIS PHARMACEUTICALS INC VIRX Chevallard Daniel R.
CEO
0 $0 320,908
(Direct)
View
2019-05-14(A)
Option Award
2019-05-16
5:57 pm
2019-05-14
2029-02-04
Regulus Therapeutics Inc. RGLS Chevallard Daniel R.
CFO
8,000 $0 8,000
(Direct)
View
2019-05-14
Option Award
2019-05-16
5:21 pm
2019-05-14
2029-02-04
Regulus Therapeutics Inc. RGLS Chevallard Daniel R.
CFO
63,414 $0 88,039
(Direct)
View
2019-02-05
Option Award
2019-02-06
4:50 pm
N/A
2029-02-04
Regulus Therapeutics Inc. RGLS Chevallard Daniel R.
CFO
30,000 $0 64,578
(Direct)
View
2019-02-05
Option Award
2019-02-06
4:50 pm
N/A
N/A
Regulus Therapeutics Inc. RGLS Chevallard Daniel R.
CFO
30,000 $0.95 64,578
(Direct)
View
2018-05-17
Option Award
2018-05-21
4:37 pm
N/A
2028-05-16
Regulus Therapeutics Inc. RGLS Chevallard Daniel R.
CFO
250,000 $0 250,000
(Direct)
View
2018-01-05
Option Award
2018-01-05
6:55 pm
N/A
2028-01-04
Regulus Therapeutics Inc. RGLS Chevallard Daniel R.
CFO
350,000 $0 350,000
(Direct)
View
(A) Indicate amendment filing.